DOT1L and leukemia: Accordingly, a combination of a DOT1L inhibitor (EPZ004777) and an MLL–menin interaction inhibitor (MI-2-2) was administered and showed dramatically improved differentiation induction and apoptosis in various MLL disease models, including primary leukemia cells, suggesting its potential as a new strategy for the treatment of leukemia in the future [214].